Merck & Co., Inc. (MRK) Stock Forecast & Price Target

Merck & Co., Inc.
Bear Case

Investors should be bearish about investing in Merck for these reasons:

• Merck faces significant competitive threats to its flagship product Keytruda, as India's Cipla and China's Qilu have partnered to launch a biosimilar version in the U.S. market ahead of the drug's expected 2028 patent expiration, which could erode the company's dominant market share in oncology.
• The company's price-to-earnings ratio stands at 120.30, which is exceptionally high and suggests that the stock is priced for perfection, leaving little room for error if future earnings growth does not meet the elevated expectations embedded in the current valuation.
• Merck's dividend payout ratio is currently 272.00%, meaning the company is paying out more in dividends than it is earning in net income, which raises concerns about the sustainability of the dividend yield if profitability does not improve significantly in the coming quarters.
• Recent insider activity has been heavily skewed toward selling, with executives such as Jennifer Zachary and Richard Deluca selling tens of thousands of shares in August 2026, which may signal that company leadership is taking advantage of the recent stock price rally to reduce their personal exposure.
• Competitors are challenging Merck's clinical superiority, with Summit Therapeutics claiming its cancer drug ivonescimab is keeping lung-cancer patients alive longer than Keytruda, posing a direct threat to the efficacy narrative that has driven Merck's recent stock price appreciation.